A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

Glabellar Frown Lines Clinical Trial

— EV-002  

Official title:

A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02334436
• Other study ID #: EV-002
• Status: Completed
• Phase: Phase 3
• Start date: January 2015
• Est. completion date: December 2015

Study information

• Verified date: March 2019
• Source: Evolus, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult subjects

Description:

Three hundred and twenty-four eligible subjects will be randomly assigned 3:1 to receive DWP-450 or placebo. Safety and efficacy will be assessed on Days 2, 7, 14, 30, 90, 120 and 150. The primary efficacy end point assesses the effectiveness of the DWP-450 against placebo on Day 30 in a superiority design.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 324
• Est. completion date: December 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects is an adult, of at least 18 years of age

• Subject is able to provide informed consent and comply with study instructions

• Subject has moderate to severe glabellar lines at maximum frown as assessed by the investigator using the GLS

• Subject has moderate to severe glabellar lines at maximum frown as assessed by the subject using the GLS

• Subject is willing and able to complete the entire course of the study

Exclusion Criteria:

• Previous treatment with botulinum toxin of any serotype in any area within the last 6 months

• Previous treatment with any facial aesthetic procedure (e.g. injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months

• Previous insertion of permanent material in the glabellar area

• Planned treatment with botulinum toxin of any serotype in any other body region during the study period

• Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)

• Energy-based or cryo-therapy based treatment of facial muscles superior to the lateral canthus

• Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (subjects can continue with their usual skin care routine)

• Subjects who may not respond to 20 Units of botulinum toxin (e.g., inability to substantially lessen glabellar frown lines even by physically spreading them apart)

• Marked facial asymmetry

• Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis

• History of facial nerve palsy

• Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin

• Any active infection in the area of the injection sites

• Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis)

• Evidence of recent alcohol or drug abuse

• Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study

• Pregnant or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception

• Known allergy or hypersensitivity to botulinum toxin preparation

• Participation in another interventional clinical study within the last 30 days

Related Conditions & MeSH terms

• Glabellar Frown Lines

Intervention

Biological:
• Botulinum toxin, Type A
Botulinum toxin, Type A

Other:
• 0.9% sterile, unpreserved saline
Placebo Comparator Arm

Locations

Country	Name	City	State
United States	The Clinical Testing Center of Beverly Hills	Beverly Hills	California

Sponsors (2)

Lead Sponsor	Collaborator
Evolus, Inc.	PPD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With a =2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject	The primary efficacy end point assesses the effectiveness of DWP-450 against placebo on Day 30. The primary efficacy measure is a composite end point. Using the GLS scale, investigators and subjects will assess the glabellar lines at Day 0 and Day 30. A subject is a responder only if both the investigator and subject independently agree that a =2 improvement has occurred from Day 0 to Day 30.; GLS is scored: 0=none, 1=mild, 2=moderate, 3=severe.	Day 30
Secondary	Percentage of Participants With a =2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject	Secondary endpoint was the proportion of subjects classified as responders on Day 90. This was a composite endpoint based on both the Investigator and subject assessments of glabellar lines at maximum frown on the GLS; a subject was a responder only if both the Investigator and subject independently agreed that a =2 point improvement had occurred from Day 0 to 90 Day.; GLS is scored: 0=none, 1=mild, 2=moderate, 3=severe.	90 Days
Secondary	Percentage of Participants With a =2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject	Secondary endpoint was the proportion of subjects classified as responders on Day 120. This was a composite endpoint based on both the Investigator and subject assessments of glabellar lines at maximum frown on the GLS; a subject was a responder only if both the Investigator and subject independently agreed that a =2 point improvement had occurred from Day 0 to 120 Day; GLS is scored: 0=none, 1=mild, 2=moderate, 3=severe.	Day 120
Secondary	Percentage of Participants With a =2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject	Secondary endpoint was the proportion of subjects classified as responders on Day 150. This was a composite endpoint based on both the Investigator and subject assessments of glabellar lines at maximum frown on the GLS; a subject was a responder only if both the Investigator and subject independently agreed that a =2 point improvement had occurred from Day 0 to 150 Day; GLS is scored: 0=none, 1=mild, 2=moderate, 3=severe.	Day 150